Walleye Capital LLC increased its position in Annexon, Inc. (NASDAQ:ANNX – Get Rating) by 366.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 245,254 shares of the company’s stock after purchasing an additional 192,727 shares during the period. Walleye Capital LLC’s holdings in Annexon were worth $670,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ANNX. Quantbot Technologies LP raised its position in Annexon by 630.8% during the first quarter. Quantbot Technologies LP now owns 9,500 shares of the company’s stock valued at $25,000 after purchasing an additional 8,200 shares during the period. Values First Advisors Inc. purchased a new stake in Annexon during the first quarter valued at approximately $33,000. Kestra Advisory Services LLC purchased a new stake in Annexon during the first quarter valued at approximately $41,000. Dynamic Technology Lab Private Ltd purchased a new stake in Annexon during the first quarter valued at approximately $41,000. Finally, Jane Street Group LLC purchased a new stake in Annexon during the first quarter valued at approximately $46,000.
Annexon Stock Performance
Shares of NASDAQ ANNX opened at $6.63 on Wednesday. The business’s 50 day moving average price is $5.49 and its 200-day moving average price is $4.04. Annexon, Inc. has a fifty-two week low of $2.06 and a fifty-two week high of $22.49. The company has a market cap of $315.71 million, a price-to-earnings ratio of -1.75 and a beta of 0.49.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Cantor Fitzgerald decreased their price objective on Annexon from $27.00 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 16th. BTIG Research began coverage on Annexon in a report on Friday, September 9th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Annexon in a report on Friday, September 16th. They issued a “buy” rating and a $12.00 price target on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon has an average rating of “Buy” and a consensus target price of $23.67.
Insider Buying and Selling
In other news, Director Muneer A. Satter acquired 2,453,988 shares of the company’s stock in a transaction that occurred on Thursday, July 7th. The shares were bought at an average price of $3.84 per share, with a total value of $9,423,313.92. Following the completion of the purchase, the director now directly owns 4,408,966 shares in the company, valued at $16,930,429.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.50% of the stock is owned by insiders.
Annexon Company Profile
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
- Get a free copy of the StockNews.com research report on Annexon (ANNX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.